t-butyl 4-(pyrimidin-5-ylamino)piperidine-1-carboxylate | 856937-63-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: t-butyl 4-(pyrimidin-5-ylamino)piperidine-1-carboxylate
• 英文别名: 4-(pyrimidin-5-ylamino)-piperidine-1-carboxylic acid tert-butyl ester；tert-butyl 4-(pyrimidin-5-ylamino)piperidine-1-carboxylate
• CAS: 856937-63-8
• 化学式: C₁₄H₂₂N₄O₂
• 分子量: 278.354
• InChiKey: STENFLRCSQYJKS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  20
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.64
• 拓扑面积：
  67.4
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  t-butyl 4-(pyrimidin-5-ylamino)piperidine-1-carboxylate 在 水 、 palladium diacetate 、 N,N-二异丙基乙胺 、 4,5-双二苯基膦-9,9-二甲基氧杂蒽 、 三氟乙酸 、 sodium t-butanolate 作用下， 以 1,4-二氧六环 、 二氯甲烷 、 甲苯 为溶剂， 反应 22.5h， 生成 N-4-trifluoromethylphenyl-N-{1-[5-(trifluoromethyl)pyrimidin-5-yl]piperidin-4-yl}pyridin-3-amine
  参考文献：
  名称：

  Two Analogues of Fenarimol Show Curative Activity in an Experimental Model of Chagas Disease

  摘要：

  Chagas disease, caused by the protozoan parasite Trypanosoma cruzi (T. cruzi), is an increasing threat to global health. Available medicines were introduced over 40 years ago, have undesirable side effects, and give equivocal results of cure in the chronic stage of the disease. We report the development of two compounds, 6 and (S)-7, with PCR-confirmed curative activity in a mouse model of established T. cruzi infection after once daily oral dosing for 20 days at 20 mg/kg 6 and 10 mg/kg (S)-7. Compounds 6 and (S)-7 have potent in vitro activity, are noncytotoxic, show no adverse effects in vivo following repeat dosing, are prepared by a short synthetic route, and have druglike properties suitable for preclinical development.

  DOI：

  10.1021/jm401610c
• 作为产物：
  描述：

  1-Boc-4-苄氨基哌啶 在 palladium on activated charcoal palladium diacetate 、 氢气 、 R-(+)-1,1'-联萘-2,2'-双二苯膦 、 sodium t-butanolate 作用下， 以 1,4-二氧六环 、 甲醇 为溶剂， 生成 t-butyl 4-(pyrimidin-5-ylamino)piperidine-1-carboxylate
  参考文献：
  名称：

  1,3,4 trisubstituted pyrrolidine CCR5 receptor antagonists bearing 4-aminoheterocycle substituted piperidine side chains

  摘要：

  A new class of 4-(aminoheterocycle)piperidine derived 1,3,4 trisubstituted pyrrolidine CCR5 antagonists is reported. Compound 4a is shown to have good binding affinity (1.8 nM) and antiviral activity in PBMC's (IC95 = 50 nM). Compound 4a also has improved PK properties relative to 1. (C) 2002 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(02)00988-5

文献信息

• PYRIDINE, QUINOLINE AND PYRIMIDINE DERIVATIVES
  申请人：Christ D. Andreas

  公开号：US20080064697A1

  公开（公告）日：2008-03-13

  This invention is concerned with compounds of the formula wherein A, R 1 to R 5 are as defined in the specification and G is a pyridine, quinoline or pyrimidine group as defined in the specification, and pharmaceutically acceptable salts thereof. The invention further relates to pharmaceutical compositions containing such compounds, to a process for their preparation and to their use for the treatment and/or prevention of diseases which are associated with the modulation of SST receptors subtype 5.

  这项发明涉及以下式的化合物 其中A，R1至R5如规范中所定义，G是规范中定义的吡啶，喹啉或嘧啶基团，以及其药用盐。该发明还涉及含有这种化合物的药物组合物，以及用于制备它们的过程以及它们用于治疗和/或预防与调节SST受体亚型5相关的疾病。
• Chemokine receptor binding compounds
  申请人：Zhou Yuanxi

  公开号：US20050277670A1

  公开（公告）日：2005-12-15

  The present invention relates to chemokine receptor binding compounds, pharmaceutical compositions and their use. More specifically, the present invention relates to modulators of chemokine receptor activity, preferably modulators of CCR5. These compounds demonstrate protective effects against infection of target cells by a human immunodeficiency virus (HIV).

  本发明涉及化学因子受体结合化合物、制药组合物及其使用。更具体地，本发明涉及化学因子受体活性调节剂，优选为CCR5的调节剂。这些化合物表现出对人类免疫缺陷病毒（HIV）感染靶细胞的保护作用。
• Pyridine, quinoline and pyrimidine derivatives
  申请人：Hoffman-La Roche Inc.

  公开号：US07939661B2

  公开（公告）日：2011-05-10

  This invention is concerned with compounds of the formula wherein A, R1 to R5 are as defined in the specification and G is a pyridine, quinoline or pyrimidine group as defined in the specification, and pharmaceutically acceptable salts thereof. The invention further relates to pharmaceutical compositions containing such compounds, to a process for their preparation and to their use for the treatment and/or prevention of diseases which are associated with the modulation of SST receptors subtype 5.

  本发明涉及如下式化合物，其中A，R1至R5如规范中所定义，G为规范中定义的吡啶、喹啉或嘧啶基团，以及其药学上可接受的盐。本发明还涉及含有这些化合物的制药组合物，它们的制备方法以及它们用于治疗和/或预防与SST受体亚型5调节相关的疾病。
• CHEMOKINE RECEPTOR BINDING COMPOUNDS
  申请人：ANORMED INC.

  公开号：EP1708703A2

  公开（公告）日：2006-10-11
• EP1708703A4
  申请人：——

  公开号：EP1708703A4

  公开（公告）日：2008-04-09